This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In her editorial, Dr DeAngelis¹ described her experience developing and enforcing JAMA's financial disclosure policy and discussed how, despite extensive efforts at education, some authors still lack clear understanding of JAMA's current disclosure requirements.

The issue of disclosure in publications is very important. Recently, the Federation of American Societies for Experimental Biology (FASEB), representing more than 80 000 biomedical researchers, developed overarching principles and voluntary standards for the conduct and management of academia-industry interactions from the scientists' perspective.² Several of these recommendations speak to the dissemination of research results. FASEB urges investigators to be aware of and adhere to individual journal policies on disclosure of industry relationships. If the researchers are unclear about these policies, contact with the editor is encouraged.

Journal policies vary widely with respect to disclosure policies. We appreciate that biomedical journals are diverse in scope, audience, and the types of research reported . . . [Full Text of this Article]

Laura M. Brockway, PhD
lbrockway@faseb.org
Office of Public Affairs
Federation of American Societies for Experimental Biology
Bethesda, Md

Leo T. Furcht, MD
Department of Laboratory Medicine and Pathology
University of Minnesota Medical School
Minneapolis

RELATED LETTER

Financial Disclosure Policies of Scientific Publications—Reply
Catherine D. DeAngelis
JAMA. 2006;296(24):2926.
EXTRACT | FULL TEXT